Literature DB >> 17011589

Alpha-lipoic acid: an inhibitor of secretory phospholipase A2 with anti-inflammatory activity.

Noor Mohamed Jameel1, Mysore A Shekhar, Bannikuppe S Vishwanath.   

Abstract

Alpha-lipoic acid (ALA) and its reduced form dihydrolipoic acid (DHLA) are powerful antioxidants both in hydrophilic and lipophylic environments with diverse pharmacological properties including anti-inflammatory activity. The mechanism of anti-inflammatory activity of ALA and DHALA is not known. The present study describes the interaction of ALA and DHALA with pro-inflammatory secretory PLA(2) enzymes from inflammatory fluids and snake venoms. In vitro enzymatic inhibition of sPLA(2) from Vipera russellii, Naja naja and partially purified sPLA(2) enzymes from human ascitic fluid (HAF), human pleural fluid (HPF) and normal human serum (HS) by ALA and DHLA was studied using (14)C-oleate labeled Escherichia coli as the substrate. Biophysical interaction of ALA with sPLA(2) was studied by fluorescent spectral analysis and circular dichroism studies. In vivo anti-inflammatory activity was checked using sPLA(2) induced mouse paw edema model. ALA but not DHLA inhibited purified sPLA(2) enzymes from V. russellii, N. naja and partially purified HAF, HPF and HS in a dose dependent manner. This data indicated that ALA is critical for inhibition. IC(50) value calculated for these enzymes ranges from 0.75 to 3.0 microM. The inhibition is independent of calcium and substrate concentration. Inflammatory sPLA(2) enzymes are more sensitive to inhibition by ALA than snake venom sPLA(2) enzymes. ALA quenched the fluorescence intensity of sPLA(2) enzyme in a dose dependent manner. Apparent shift in the far UV-CD spectra of sPLA(2) with ALA indicated change in its alpha-helical confirmation and these results suggest its direct interaction with the enzyme. ALA inhibits the sPLA(2) induced mouse paw edema in a dose dependent manner and confirms the sPLA(2) inhibitory activity in vivo also. These data suggest that ALA may act as an endogenous regulator of sPLA(2) enzyme activity and suppress inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011589     DOI: 10.1016/j.lfs.2006.08.032

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Integrated Treatment With Stapled Haemorrhoidopexy and Proctonorm® of Haemorrhoidal Disease.

Authors:  Giuliano Reboa; Marco Gipponi; Piero Fregatti; Francesca Depaoli
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

2.  Chemical modification of ascorbic acid and evaluation of its lipophilic derivatives as inhibitors of secretory phospholipase A(2) with anti-inflammatory activity.

Authors:  Riyaz Mohamed; K K Dharmappa; Shaista Tarannum; N M Jameel; S A Kannum; H S Ashrafulla; Lokanath Rai; Cletus Jmd' Souza; M A Shekhar; Bannikuppe S Vishwanath
Journal:  Mol Cell Biochem       Date:  2010-08-22       Impact factor: 3.396

3.  Syringol isolated from Eleusine coracana (L.) Gaertn bran suppresses inflammatory response through the down-regulation of cPLA2, COX-2, IκBα, p38 and MPO signaling in sPLA2 induced mice paw oedema.

Authors:  M D Milan Gowda; K Jayachandra; Vikram Joshi; Vaddarahally N Manjuprasanna; Gotravalli V Rudresha; Devadasan Velmurugan; Raman Pachaiappan; Noor Mohamed Jameel; Bannikuppe S Vishwanath
Journal:  Inflammopharmacology       Date:  2022-05-31       Impact factor: 5.093

4.  Therapeutic application of natural inhibitors against snake venom phospholipase A(2).

Authors:  Ramar Perumal Samy; Ponnampalam Gopalakrishnakone; Vincent Tk Chow
Journal:  Bioinformation       Date:  2012-01-06

5.  Hyperbilirubinemia exaggerates endotoxin-induced hypothermia.

Authors:  Eszter Pakai; Andras Garami; Tatiane B Nucci; Andrei I Ivanov; Andrej A Romanovsky
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Effects of Alpha-Lipoic Acid Supplementation on Cardiovascular Disease Risk Factors in β-Thalassemia Major Patients: A Clinical Trial Crossover Study.

Authors:  Khadijeh Jamshidi; Hadi Abdollahzad; Mostafa Nachvak; Mansour Rezaei; Mohammad Reza Golpayegani; Elham Sharifi Zahabi
Journal:  J Blood Med       Date:  2020-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.